The second-generation inhibitor 18F-DCFPyl, developed by the same group [2], showed five times higher PSMA affinity, improved tumor uptake, and rapid plasma clearance, resulting in higher tumor-to-blood and tumor-to-background ratios and lower accumulation in the liver compared to 18F-DCFBC. The gene discussed is FOLH1; the disease is neoplasm.